MSB $1 Party, page-527

@bariscan90

Interesting question !

Would’nt it be funny if Prof Amy Lightner of the Cleveland Clinic announces further interim data confirming a continuation of further superlative Phase 2 clinical responses using Remestemcel in refractory UC and Crohns at Digestive week in less than a fortnight ? I mean you can explain four patients in a row achieving endoscopic remission and the control showing no improvement or worsening can’t you ? Another pure fluke? I mean there’s no way that the cross over patients will improve is there ? ..not to mention any other additional new patient data that Silviu specifically referred to as being imminent in a recent announcement. I read one analyst profiling the market for Ulcerative Colitis being around $2.7 bn a year in the US. The normal remission rates for ENDOSCOPIC and histologic remission are normally no higher than about 30% even with combination therapies…but we know its just another fluke, don’t we ? I mean I am sure you understand the relevance of F/C levels ?

Would’nt it be funny if the FDA decides to grant accelerated approval for Rexlemestemcel ,,,and we secure a pathway for single trial approval for use with ischemic and or diabetics ?

Would’nt it be funny if we get a financial or industry partner for CLBP or CHF ? I mean who could possibly be interested in those indications ?

Geez….its good to speculate , isn’t it ?